Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated May 31, 2024, titled "Results of the Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024".
Press Release May 31 2024
Filed with NSE ·
6ix hasn’t read this filing yet.
Sun Pharmaceutical Industries Limited on 6ix
Earlier from Sun Pharmaceutical Industries
- Press Release May 23 2024
- Press Release Mar 19 2024
- Press Release Feb 12 2024
- Press Release Jan 31 2024
- Press Release Jan 17 2024
Later from Sun Pharmaceutical Industries
- Press Release Jun 04 2024
- Press Release Jun 14 2024
- Sun Pharma - Oral Presentation at EULAR 2024 of Data from Global Phase 2b Clinical Trial Demonstrates Durability of Pain Relief After a Single Injection of MM-II in Patients with Painful Knee Osteoarthritis
- Sun Pharmaceutical Industries Limited Press Release Jun 21 2024
- Press Release Jun 22 2024
Follow Sun Pharmaceutical Industries into a list and get an email when it puts out news.
Follow Sun Pharmaceutical Industries